Sign in
CompletedPhase 4

Dexamethasone With Ropivacaine for PENG Block in Total Hip Arthroplasty

Key facts

Who runs it
Poznan University of Medical Sciences
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
7 Nov 2024
Ended
30 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ropivacaine
  • Ropivacaine+Dexamethasone
Record updated
11 July 2025

Who can take part

Age
65 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • patients scheduled for total hip arthroplasty
  • patients aged >65 and <100 years
  • patients able to provide informed consent
  • patients able to reliably report symptoms to the research team

Who cannot take part

  • inability to provide first-party consent due to cognitive impairment or a language barrier

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Does adding Dexamethasone to the Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty reduce the dose of ropivacaine?

The 2 groups in the trial

  • RopivacaineExisting treatment, for comparison

    Ultrasound-guided PENG block - 20ml 0,2% ropivacaine

  • Ropivacaine + DexamethasoneExisting treatment, for comparison

    Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pericapsular Nerve Group Block With 20 ml 0.2% Ropivacaine vs 10ml 0.2% Ropivacaine and Dexamethasone in Total Hip Arthroplasty: A Randomized Controlled Trial
Record updated
11 July 2025